Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.51 |
| ▸ | PRCP | P42785 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 5/20 | 0.44 |
| ▸ | HTR2B | P41595 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10788824 | 1.00 | TERT (0.51) | TERTPRCPHTR2CHTR2BKDM4E | |
| SCHEMBL30481218 | 1.00 | TERT (0.51) | TERTPRCPHTR2CHTR2BKDM4E | |
| SCHEMBL31142126 | 1.00 | TERT (0.51) | TERTPRCPHTR2CHTR2BKDM4E | |
| SCHEMBL10788841 | 1.00 | TERT (0.51) | TERTPRCPHTR2CHTR2BKDM4E | |
| SCHEMBL620067 | 0.93 | PRCP (0.55) | TERTPRCPHTR2CHTR2BKDM4E | |
| SCHEMBL620066 | 0.93 | PRCP (0.55) | TERTPRCPHTR2CHTR2BKDM4E | |
| SCHEMBL8789170 | 0.93 | PRCP (0.55) | TERTPRCPHTR2CHTR2BKDM4E | |
| SCHEMBL6372058 | 0.88 | PRCP (0.50) | TERTPRCPHTR2CHTR2BKDM4E | |
| Glycine SCHEMBL2933526 | 0.87 | PRCP (0.50) | TERTPRCPHTR2CHTR2BKDM4E | |
| Trifluoroacetic Acid SCHEMBL19209820 | 0.84 | HTR2C (0.48) | TERTPRCPHTR2CHTR2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408802-B1 | CYCLIC AMINO ACID MOLECULES AND METHODS OF PREPARING THE SAME | GOVERNING COUNCIL UNIV TORONTO (CA) | 2017-05-03 | — | — | EP | disclosed |
| US-9260479-B2 | Cyclic amino acid molecules and methods of preparing the same | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2016-02-16 | — | — | US | disclosed |
| US-20120065366-A1 | CYCLIC AMINO ACID MOLECULES AND METHODS OF PREPARING THE SAME | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065366-A1 | CYCLIC AMINO ACID MOLECULES AND METHODS OF PREPARING THE SAME | DNPEP, ANPEP, BCAT1 | TERT 3443/4885PRCP 336/4885HTR2C 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.